Tags

Type your tag names separated by a space and hit enter

L-dopa therapy for Parkinson's disease: past, present, and future.
Parkinsonism Relat Disord. 2009 Jan; 15 Suppl 1:S3-8.PR

Abstract

Dopamine (DA) supplementation therapy by l-dopa for Parkinson's disease (PD) was established around 1970. The dose of l-dopa can be reduced by the combined administration of inhibitors of peripheral l-amino acid decarboxylase (AADC), catechol O-methyltransferase (COMT), or monoamine oxidase B (MAO B). DA in the striatum may be produced from exogenously administered l-dopa by various AADC-containing cells, such as serotonin neurons. The long-term administration of l-dopa in PD patients may produce l-dopa-induced dyskinesia (LID), which may be due to chronic overstimulation of supersensitive DA D1 receptors. l-dopa may be used in combination with various new strategies such as gene therapy or transplantation in the future.

Authors+Show Affiliations

Department of Pharmacology, School of Medicine, Fujita Health University, Toyoake, Aichi 470-1192, Japan. tnagatsu@fujita-hu.ac.jpNo affiliation info available

Pub Type(s)

Historical Article
Journal Article
Review

Language

eng

PubMed ID

19131039

Citation

Nagatsua, Toshiharu, and Makoto Sawadab. "L-dopa Therapy for Parkinson's Disease: Past, Present, and Future." Parkinsonism & Related Disorders, vol. 15 Suppl 1, 2009, pp. S3-8.
Nagatsua T, Sawadab M. L-dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat Disord. 2009;15 Suppl 1:S3-8.
Nagatsua, T., & Sawadab, M. (2009). L-dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism & Related Disorders, 15 Suppl 1, S3-8. https://doi.org/10.1016/S1353-8020(09)70004-5
Nagatsua T, Sawadab M. L-dopa Therapy for Parkinson's Disease: Past, Present, and Future. Parkinsonism Relat Disord. 2009;15 Suppl 1:S3-8. PubMed PMID: 19131039.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - L-dopa therapy for Parkinson's disease: past, present, and future. AU - Nagatsua,Toshiharu, AU - Sawadab,Makoto, PY - 2009/1/10/entrez PY - 2009/3/14/pubmed PY - 2009/4/1/medline SP - S3 EP - 8 JF - Parkinsonism & related disorders JO - Parkinsonism Relat Disord VL - 15 Suppl 1 N2 - Dopamine (DA) supplementation therapy by l-dopa for Parkinson's disease (PD) was established around 1970. The dose of l-dopa can be reduced by the combined administration of inhibitors of peripheral l-amino acid decarboxylase (AADC), catechol O-methyltransferase (COMT), or monoamine oxidase B (MAO B). DA in the striatum may be produced from exogenously administered l-dopa by various AADC-containing cells, such as serotonin neurons. The long-term administration of l-dopa in PD patients may produce l-dopa-induced dyskinesia (LID), which may be due to chronic overstimulation of supersensitive DA D1 receptors. l-dopa may be used in combination with various new strategies such as gene therapy or transplantation in the future. SN - 1353-8020 UR - https://www.unboundmedicine.com/medline/citation/19131039/L_dopa_therapy_for_Parkinson's_disease:_past_present_and_future_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1353-8020(09)70004-5 DB - PRIME DP - Unbound Medicine ER -